CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Sanij, Elaine
Hannan, Katherine M
Xuan, Jiachen
Yan, Shunfei
Ahern, Jessica E
Trigos, Anna S
Brajanovski, Natalie
Son, Jinbae
Chan, Keefe T
Kondrashova, Olga
Lieschke, Elizabeth
Wakefield, Matthew J
Frank, Daniel
Khanna, Kum Kum
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2020
Size
File type(s)
Location
Abstract

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cancer (HGSOC). Here, we demonstrate CX-5461, the first-in-class inhibitor of RNA polymerase I transcription of ribosomal RNA genes (rDNA), induces replication stress and activates the DNA damage response. CX-5461 co-operates with PARPi in exacerbating replication stress and enhances therapeutic efficacy against homologous recombination (HR) DNA repair-deficient HGSOC-patient-derived xenograft (PDX) in vivo. We demonstrate CX-5461 has a different sensitivity spectrum to PARPi involving MRE11-dependent degradation of replication forks. Importantly, CX-5461 exhibits in vivo single agent efficacy in a HGSOC-PDX with reduced sensitivity to PARPi by overcoming replication fork protection. Further, we identify CX-5461-sensitivity gene expression signatures in primary and relapsed HGSOC. We propose CX-5461 is a promising therapy in combination with PARPi in HR-deficient HGSOC and also as a single agent for the treatment of relapsed disease.

Journal Title

NATURE COMMUNICATIONS

Conference Title
Book Title
Edition
Volume

11

Issue

1

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/.

Item Access Status
Note
Access the data
Related item(s)
Subject

Biological sciences

Biomedical and clinical sciences

Science & Technology

Multidisciplinary Sciences

Science & Technology - Other Topics

RNA-POLYMERASE I

HOMOLOGOUS-RECOMBINATION

Persistent link to this record
Citation

Sanij, E; Hannan, KM; Xuan, J; Yan, S; Ahern, JE; Trigos, AS; Brajanovski, N; Son, J; Chan, KT; Kondrashova, O; Lieschke, E; Wakefield, MJ; Frank, D; Khanna, KK; et al., RB, CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer, NATURE COMMUNICATIONS, 2020, 11 (1)

Collections